论文部分内容阅读
目的:评价美罗培南治疗老年卒中相关性肺炎的临床疗效。方法:回顾性分析104例老年卒中相关性肺炎患者的临床资料,根据是否采取美罗培南治疗进行分组;对照组46例,采取头孢他啶治疗;观察组58例,采取美罗培南治疗;对比两组患者的退热时间、湿啰音消失时间、白细胞计数恢复正常时间及住院时间,综合评价患者的临床疗效,并作对比分析。结果:观察组患者的退热时间、湿啰音消失时间、白细胞计数恢复正常时间及住院时间均短于对照组,差异具有统计学意义(P<0.05);观察组临床总有效率为89.66%,大于对照组的73.91%,差异具有统计学意义(P<0.05);两组患者的不良反应发生率比较,差异无统计学意义(P>0.05),且不良反应较轻微,无需特别处理,治疗前后肝、肾功能无异常。结论:美罗培南治疗老年卒中相关性肺炎的临床疗效确切,可加快缓解临床症状和体征,协同提高临床疗效,且安全性高。
Objective: To evaluate the clinical efficacy of Meropenem in the treatment of senile stroke-associated pneumonia. Methods: A retrospective analysis of 104 elderly patients with stroke-associated pneumonia clinical data, according to whether or not to take Meropenem treatment group; control group of 46 patients treated with ceftazidime; observation group of 58 patients taking meropenem treatment; compared two groups of patients Antipyretic time, wet rales disappear time, white blood cell count returned to normal time and hospital stay, a comprehensive evaluation of the clinical efficacy of patients, and for comparative analysis. Results: The antipyretic time, the disappearance time of wet rales, the normal time of white blood cell count and hospital stay in observation group were shorter than those in control group (P <0.05). The total clinical effective rate in observation group was 89.66% , Which was significantly higher than that of the control group (73.91%) (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05), and the adverse reaction was mild with no special treatment, Liver and kidney function before and after treatment was normal. Conclusion: Meropenem is effective in the treatment of stroke-associated pneumonia in elderly patients, which can accelerate the relief of clinical symptoms and signs and improve the clinical efficacy in combination with high safety.